Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections

References

• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51(3):291–298.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). J Antimicrob Chemother. 2015;70(7):2053–2056.
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S 3–4.
   Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66(1):82–98.
   PubMedGoogle Scholar
• Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016 Apr;29(2):109–115.
   PubMed Web of Science ®Google Scholar
• Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. Infect Dis Ther. 2015;4(3):245–258.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Two new drugs for skin and skin structure infections. Med Lett Drugs Ther. 2014;56(1449):73–75.
   PubMed Web of Science ®Google Scholar
• Aryun K, Kuti JL, Nicolau DP. Dalbavancin. Expert Opin Investig Drugs. 2007;16(5):717–733.
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacother J Hum Pharmacol Drug Ther. 2008;28(4):458–468.
   Google Scholar
• Mendes RE, Farrel DJ, Sader HS, et al. Update of the telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2013) when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis. 2015;81(4):275–279.
   PubMed Web of Science ®Google Scholar
• Kenneth PK, Borgert SJ. Beyond. Vancomycin: the tail of the lipoglycopeptides. New Drug Rev Clin Ther. 2015;37(12):2619–2636.
   Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–886.
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl. 2):ii15–20.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 gram positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–1263.
   PubMed Web of Science ®Google Scholar
• Jones RN, Stilwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program. Diagn Microbiol Infect Dis. 2006;54(2):149–153.
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Goldstein EJ. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis. 2014;79(4):438–440.
   PubMed Web of Science ®Google Scholar
• Streit JM, Sader HS, Fritsche T, et al. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn Microbiol Infect Dis. 2005;53:307–310.
   PubMed Web of Science ®Google Scholar
• Guay DR. Dalbavancin: an investigational glycopeptide. Expert Rev Anti Infect Ther. 2004;2(6):845–852.
   PubMedGoogle Scholar
• Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii 25–30.
   Web of Science ®Google Scholar
• Jabes D, Candiani G, Romano G, et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother. 2004;48(4):1118–1123.
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298–1303.
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940–945.
   PubMed Web of Science ®Google Scholar
• Marbury T, Dowell JA, Seltzer E, et al. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49(4):465–476.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Goldstein BP, Buckwalter M, et al. Pharmacokinetic pharmacodynamic modeling of dalbavancin, a novel glycopeptides antibiotic. J Clin Pharmacol. 2008;48(9):1063–1068.
   PubMed Web of Science ®Google Scholar
• Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45(11):1279–1287.
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60(3):681–684.
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005;55(Suppl. 2):ii31–5.
   PubMed Web of Science ®Google Scholar
• Esposito S, Noviello S, Leone S. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Infez Med. 2015;23(4):313–317.
   PubMedGoogle Scholar
• Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–940.
   PubMed Web of Science ®Google Scholar
• Dalvance (DAL) for injection [package insert]. Chicago, IL: Durata; Rev 05/14.
   Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–e52.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Dalbavancin: a review for dermatologists. Dermatol Online J. 2006;12(4):6.
   Google Scholar
• Xydalba. Summary of product characteristics. [cited 2017 Aug 13]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human_med_001848.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Juul JJ, Mullins CF, Peppard WJ, et al. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin. Ther Clin Risk Manag. 2016;12:225–232.
   PubMed Web of Science ®Google Scholar
• Salem AH, Zhanel GG, Ibrahim SA, et al. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41(6):437–443.
   PubMed Web of Science ®Google Scholar
• Dowell JA, Buckwalter M, Seltzer E, et al. Dalbavancin penetration in to skin supports once weekly dosing. Clin Microbiol Infect. 2005;11(S2):272 (Abstract P-895).
   Google Scholar
• Bulgheroni A, Jabes D, Pollini W et al. Dalbavancin uptake by murine macrophages. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 30–2 Oct–Nov 2004; A–1490.
   Google Scholar
• Dunne MW, Puttagunta S, Sprenger CR, et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–1855.
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374–380.
   PubMed Web of Science ®Google Scholar
• Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Expert Rev Anti Infect Ther. 2007;5(4):557–571.
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Cada DJ, Ingram K, Baker DE. Dalbavancin. Formulary Drug Rev. 2014;49(9):851–861.
   Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–551.
   PubMed Web of Science ®Google Scholar
• [ cited 2017 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02814916
   Google Scholar
• [ cited 2017 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02940730
   Google Scholar
• [ cited 2017 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02961764
   Google Scholar
• Dunne M, Das AF, Puttagunta S Poster presented at IDWeek 2013, October 2–6; San Francisco, California, USA; 2013.
   Google Scholar
• Trevino J, Bayon C, Arda A, et al. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Chemistry. 2014;20(24):7363–7372.
   PubMed Web of Science ®Google Scholar
• Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004;44(7):689–695.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45(4):393–398.
   PubMed Web of Science ®Google Scholar
• Durata Therapeutics International B.V.. Dalbavancin for injection for treatment of acute bacterial skin and skin structure infections. Briefing document. FDA Anti-Infective Drugs Advisory Committee, Report No: ND 021-883; 2014.
   Google Scholar
• U.S. Food and Drug Administration (FDA). Examining ways to combat antibiotic resistance and foster new drug development. June 14, 2016. [cited 2017 Nov]. Available from: https://www.fda.gov/newsevents/testimony/ucm506976.htm.
   Google Scholar
• Development history and FDA approval process for dalvance process [cited 2017 Nov] . Available from: https://www.drugs.com/history/dalvance.html
   Google Scholar
• European Medicines Agency. Xydalba authorisation details [Internet]. 2015 [cited 2015 Apr 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human_med_001848.jsp&mid=WC0b01ac058001d124
   Google Scholar
• [ cited 2017 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT03148756
   Google Scholar
• Dryden MS. Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection? Curr Opin Infect Dis. 2015 Apr;28(2):117–124.
   PubMed Web of Science ®Google Scholar
• McCurdy SP, Jones RN, Mendes RE, et al. In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program. Antimicrob Agents Chemother. 2015;59(8):5007–5009.
   PubMed Web of Science ®Google Scholar
• Vibativ [package insert]. South San Francisco, CA: Theravance Inc; 2014 Nov.
   Google Scholar
• ORBACTIV [package insert]. Parsippany, NJ: The Medicines Company; 2014 Sep.
   Google Scholar
• Sivextro [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc; 2014 June.
   Google Scholar
• Esposito S, Noviello S, Leone S, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents. 2004 Nov;24(5):473–478.
   PubMed Web of Science ®Google Scholar